Corner Therapeutics Revenue and Competitors

Boston, MA USA

Location

$54M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Corner Therapeutics's estimated annual revenue is currently $7.1M per year.(i)
  • Corner Therapeutics's estimated revenue per employee is $155,000
  • Corner Therapeutics's total funding is $54M.

Employee Data

  • Corner Therapeutics has 46 Employees.(i)
  • Corner Therapeutics grew their employee count by 18% last year.

Corner Therapeutics's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
CofounderReveal Email/Phone
3
Chief Technology OfficerReveal Email/Phone
4
Chief Financial Officer, Chief Business OfficerReveal Email/Phone
5
VP R&DReveal Email/Phone
6
VP, OperationsReveal Email/Phone
7
Director ImmunologyReveal Email/Phone
8
Associate Director Human Resources & Business AdministrationReveal Email/Phone
9
Director DiscoveryReveal Email/Phone
10
Laboratory Operations ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.7M82-45%$107.3MN/A
#2
$0.2M1-50%N/AN/A
#3
$6.2M4021%N/AN/A
#4
$42.2M2184%$165MN/A
#5
$14.6M94-37%$312.8MN/A
#6
$0.3M2-67%N/AN/A
#7
$235M366-5%$340.9MN/A
#8
$56M289-7%$7.6MN/A
#9
$4.7M6136%N/AN/A
#10
$2M138%N/AN/A
Add Company

What Is Corner Therapeutics?

Corner is pioneering a new class of immunotherapies. Our versatile dendritic cell hyperactivation (hDC) platform is unique in its ability to address a virtually unbounded range of cancers and infectious diseases. Our platform technology induces exceptional memory T cell responses that provide robust and durable immunity. Corner seeks to transform standard of care, ushering in a new era of robust, rapid, patient-friendly and low-cost immunotherapies – even for the most difficult to treat diseases.

keywords:N/A

$54M

Total Funding

46

Number of Employees

$7.1M

Revenue (est)

18%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$6.4M4631%N/A
#2
$9.9M462%N/A
#3
$12.1M470%N/A
#4
$9.6M487%N/A
#5
$15M4820%N/A